| 何 洁,严 玲,杨屹云,贾 倞,张永明.阿托伐他汀对老年慢性阻塞性肺疾病继发肺动脉高压患者肺功能、血管内皮功能和炎症因子的影响[J].现代生物医学进展英文版,2020,(5):980-983. |
| 阿托伐他汀对老年慢性阻塞性肺疾病继发肺动脉高压患者肺功能、血管内皮功能和炎症因子的影响 |
| Effects of Atorvastatin on Pulmonary Function, Vascular Endothelial Function and Inflammatory Factors in Elderly Patients with Chronic Obstructive Pulmonary Disease and Secondary Pulmonary Hypertension |
| Received:December 06, 2019 Revised:December 30, 2019 |
| DOI：10.13241/j.cnki.pmb.2020.05.040 |
| 中文关键词: 阿托伐他汀 老年 慢性阻塞性肺疾病 肺动脉高压 肺功能 血管内皮功能 炎症因子 |
| 英文关键词: Atorvastatin Elderly Chronic obstructive pulmonary disease Pulmonary hypertension Pulmonary function Vascular endothelial function Inflammatory factors |
| 基金项目:北京市科技计划项目（D141100004203014） |
| Author Name | Affiliation | E-mail | | HE Jie | Department of Respiration, China Japan Friendship Hospital, Beijing, 100029, China | 18610065760@126.com | | YAN Ling | Department of Respiration, China Japan Friendship Hospital, Beijing, 100029, China | | | YANG Yi-yun | Department of Respiration, China Japan Friendship Hospital, Beijing, 100029, China | | | JIA Liang | Department of Respiration, China Japan Friendship Hospital, Beijing, 100029, China | | | ZHANG Yong-ming | Department of Respiration, China Japan Friendship Hospital, Beijing, 100029, China | |
|
| Hits: 874 |
| Download times: 460 |
| 中文摘要: |
| 摘要 目的：探讨阿托伐他汀对老年慢性阻塞性肺疾病（COPD）继发肺动脉高压（PH）患者肺功能、血管内皮功能和炎症因子的影响。方法：将我院于2017年3月~2019年9月收治的86例老年COPD继发PH患者按随机数表法分为对照组（n=43）和研究组（n=43），对照组给予常规治疗，研究组在其基础上联合使用阿托伐他汀治疗。比较两组患者治疗后临床疗效，治疗前后肺功能、血管内皮功能以及炎症因子水平，统计两组患者治疗期间不良反应发生情况。结果：研究组患者临床总有效率为93.02%，显著高于对照组患者的76.74%（P<0.05）。两组患者治疗后最大呼气峰流速（PEF）、第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、第1秒用力呼气容积占用力肺活量之比（FEV1/FVC）、一氧化氮（NO）均较治疗前升高，且研究组高于对照组（P<0.05）。内皮素-1（ET-1）、超敏C-反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）、白介素-6（IL-6）以及白介素-8（IL-8）较治疗前降低，且研究组低于对照组（P<0.05）。两组治疗期间均未出现不良反应。结论：阿托伐他汀治疗老年慢性阻塞性肺疾病继发肺动脉高压患者的疗效令人满意，可显著改善患者肺功能、血管内皮功能，减轻炎症反应，适于临床推广应用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of atorvastatin on pulmonary function, vascular endothelial function and inflammatory factors in elderly patients with chronic obstructive pulmonary disease (COPD) secondary to pulmonary hypertension (PH). Methods: 86 elderly patients with COPD secondary pH admitted to our hospital from March 2017 to September 2019 were divided into control group (n=43) and study group (n=43) according to the random number table method. The control group was given routine treatment, and the study group was treated with atorvastatin on this basis. The clinical effect, pulmonary function, vascular endothelial function and inflammatory factors levels in the two groups before treatment and after treatment were compared, and the adverse reactions of the two groups during the treatment were counted. Results: The total clinical effective rate of the study group was 93.02%, which was significantly higher than that of the control group (76.74%) (P<0.05). forced vital capacity(VC), forced expiratory volume in the first second (FEV1), peak expiratory flow rate (PEF), forced expiratory volume in the first second (FEV1/FVC) and nitric oxide(NO) of the two groups were higher than than before treatment, which in the research group were higher than the control group (all P<0.05). Endothelin-1 (ET-1), high sensitive C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8) were lower than before treatment, which in the research group were lower than the control group(all P<0.05). There were no adverse reactions in the two groups during the treatment. Conclusion: The therapeutic effect of atorvastatin on elderly patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease is satisfactory, which can improve the pulmonary function, vascular endothelial function and reduce the inflammatory response in elderly patients with chronic obstructive pulmonary disease secondary to pulmonary hypertension, which is suitable to popularize in clinical application. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
